NCT05014360View on ClinicalTrials.gov

A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

February 15, 2023

Study Completion Date

February 15, 2023

Conditions
Adenomatous Polyposis Coli
Interventions
DRUG

JNJ-64251330

JNJ-64251330 tablets will be administered orally.

Trial Locations (16)

8036

Hosp. Clinic I Provincial de Barcelona, Madrid

13385

APHM Hopital Timone, Marseille

31008

Clinica Univ. de Navarra, Pamplona

33136

University of Miami, Miami

53127

Universitatsklinikum Bonn, Bonn

69437

Hopital Edouard Herriot - CHU Lyon, Lyon

77030

University of Texas MD Anderson Cancer Center, Houston

91010

City of Hope, Duarte

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

1105 AZ

Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam

00 935

Pan American Center for Oncology Trials LLC, Río Piedras

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT05014360 - A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis | Biotech Hunter | Biotech Hunter